Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""IMMUNOTHERAPY"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 672
Tytuł:
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)].
Corporate Authors:
Society of Cancer Precision Medicine of Chinese Anti-Cancer Association
Lung Cancer Expert Group of Chinese Medical Journal
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Sep 23; Vol. 45 (9), pp. 717-740.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Immunotherapy*
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Consensus ; Mutation ; Tumor Microenvironment ; China
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
Autorzy:
Ren ZG; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Xu Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hua ZZ; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Mo ZY; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Wang LW; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Shi GB; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Liu WL; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Sun W; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zheng BQ; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wang CM; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jin YJ; Department of Orthopedics, Shanghai Electric Power Hospital, Shanghai 200050, China.
Chen Y; Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Nov 23; Vol. 45 (11), pp. 973-980.
Typ publikacji:
Observational Study; English Abstract; Journal Article
MeSH Terms:
Melanoma*/drug therapy
Melanoma*/pathology
Skin Neoplasms*/drug therapy
Skin Neoplasms*/pathology
Humans ; Antibodies, Monoclonal/therapeutic use ; Apoptosis ; China ; Disease-Free Survival ; East Asian People ; Immunotherapy ; Interferon-alpha/therapeutic use ; Lymphatic Metastasis ; Programmed Cell Death 1 Receptor/therapeutic use ; Melanoma, Cutaneous Malignant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Efficacy and safety evaluation of immunotherapy combined with targeted therapy as second-line treatment in patients with metastatic non-clear cell renal cell carcinoma].
Autorzy:
Wang J; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Wei WS; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Jiang LJ; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Zhang ZL; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Guo SJ; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Han H; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Zhou FJ; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Dong P; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Aug 23; Vol. 45 (8), pp. 704-708.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/drug therapy
Kidney Neoplasms*/drug therapy
Humans ; Immunotherapy/adverse effects ; Retrospective Studies
SCR Disease Name:
Clear-cell metastatic renal cell carcinoma
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Clinical analysis of immunotherapy rechallenge in advanced gastric cancer].
Autorzy:
Zhang XX; Department of Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Zhengzhou 450008, China.
Yang XF; Department of Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Zhengzhou 450008, China.
Li S; Department of Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Zhengzhou 450008, China.
Wu C; Department of Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Zhengzhou 450008, China.
Hou XF; Department of Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Cancer Hospital of Henan Province, Zhengzhou 450008, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Jul 23; Vol. 45 (7), pp. 605-612.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/pathology
Humans ; Retrospective Studies ; Prospective Studies ; Antibodies, Monoclonal/therapeutic use ; Immunotherapy/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Autorzy:
Zhou SY; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Shi YK; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2018 Jul 23; Vol. 40 (7), pp. 490-492.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy/*methods
Neoplasms/*therapy
Receptors, Antigen, T-Cell/*immunology
Hematologic Neoplasms/therapy ; Humans ; Immunotherapy, Adoptive ; Neoplasms/pathology ; T-Lymphocytes
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Immune checkpoint inhibitors-related hyperprogressive disease: a case report].
Autorzy:
Zhang JY; Department of Gastroenterology, Beijing Hepingli Hospital, Beijing 100013, China.
Peng YM; Department of Oncology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing 102400, China.
Tan KX; Graduate Student College, Beijing University of Chinese Medicine, Beijing 100029, China.
Shen W; Graduate Student College, Beijing University of Chinese Medicine, Beijing 100029, China.
Zhang X; Graduate Student College, Beijing University of Chinese Medicine, Beijing 100029, China.
Sun CY; Graduate Student College, Beijing University of Chinese Medicine, Beijing 100029, China.
Cui HJ; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2021 Sep 23; Vol. 43 (9), pp. 979-980.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Immune Checkpoint Inhibitors*
Immunotherapy*
Disease Progression ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Expert consensus on PD-L1 expression testing in esophageal carcinoma in China].
Autorzy:
Xue LY; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li Y; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Huang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Corporate Authors:
Esophageal Cancer Cooperative Group of Cancer Pathology Committee of China Anti-Cancer Association
Esophageal Cancer Committee of China Anti-Cancer Association
Esophageal Cancer Expert Committee of Chinese Society of Clinical Oncology
Esophageal Disease Group of Thoracic and Cardiovascular Surgery Society of Chinese Medical Association
Esophageal Surgery Expert Committee of Thoracic Surgery Branch of Chinese Medical Doctor Association
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Apr 23; Vol. 45 (4), pp. 291-297.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Esophageal Neoplasms*/diagnosis
Esophageal Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Humans ; B7-H1 Antigen/metabolism ; Immune Checkpoint Inhibitors/therapeutic use ; Consensus ; Immunotherapy/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
Autorzy:
Min JT; Department of Basic Medicine, Bengbu Medical College, Bengbu 233017, China.
Zhang L; Department of Life Science, Bengbu Medical College, Bengbu 233017, China.
Long CR; Department of Basic Medicine, Bengbu Medical College, Bengbu 233017, China.
Fan HL; Department of Basic Medicine, Bengbu Medical College, Bengbu 233017, China.
Li ZZ; Department of Life Science, Bengbu Medical College, Bengbu 233017, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Apr 23; Vol. 45 (4), pp. 322-329.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Receptors, Chimeric Antigen*/genetics
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Ovarian Neoplasms*
Humans ; Female ; CD8-Positive T-Lymphocytes ; Interleukin-2/pharmacology ; Tumor Necrosis Factor-alpha ; Cell Line, Tumor ; HEK293 Cells ; Immunotherapy, Adoptive
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Clinical practice guideline for stage Ⅳ primary lung cancer in China (2023 edition)].
Corporate Authors:
Chinese Association for Clinical Oncologists
Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Jan 23; Vol. 45 (1), pp. 1-30.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Lung Neoplasms*/diagnosis
Lung Neoplasms*/drug therapy
Humans ; Immunotherapy ; Molecular Targeted Therapy ; China/epidemiology ; Medical Oncology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[A review of immune-related adverse events associated with immunotherapy].
Autorzy:
Fang Y; GCP center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yu Y
Wu DW
Fang H
Huang HY
Wang SH
Yu AQ
Sun C
Bai Y
Wang H
Li N
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2020 Jan 23; Vol. 42 (1), pp. 17-21.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*
Neoplasms*/therapy
China ; Humans ; Incidence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Retrospectively analysis of characteristics and risk factors of immune treatment-related hepatic adverse events in malignant tumor].
Autorzy:
Li SL; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
Gao XP; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Chen QQ; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Fu XH; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Zhao Y; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Duan JM; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Tang YQ; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Sun J; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Li JL; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhou QM; Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518000, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2020 Jan 23; Vol. 42 (1), pp. 50-54.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*/adverse effects
Liver Diseases*/etiology
Neoplasms*/therapy
Female ; Humans ; Liver ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[Clinical practice guideline for stage Ⅳ primary lung cancer in China(2020 version)].
Corporate Authors:
Chinese Association for Clinical Oncologists
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2020 Jan 23; Vol. 42 (1), pp. 1-16.
Typ publikacji:
Journal Article
MeSH Terms:
Immunotherapy*
Lung Neoplasms*/therapy
Molecular Targeted Therapy*
China ; Humans ; Practice Guidelines as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Research Progress on Tumor Metabolic Biomarkers in Liquid Biopsy of Lung Cancer. (English)
Autorzy:
Shishi ZOU
Ning LI
Tianyu ZHANG
Qing GENG
Pokaż więcej
Temat:
AMINO acid metabolism
GLUCOSE metabolism
LIPID metabolism
PURINE metabolism
IMMUNOTHERAPY
BODY fluid examination
TUMOR markers
CANCER chemotherapy
LUNG tumors
DRUG efficacy
METABOLOMICS
DISEASE progression
Źródło:
Chinese Journal of Lung Cancer; Feb2024, Vol. 27 Issue 2, p126-132, 7p
Czasopismo naukowe
Szczegóły
Tytuł:
Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations. (English)
Autorzy:
Caicun ZHOU
Pokaż więcej
Temat:
CONSENSUS (Social sciences)
DIFFUSION of innovations
IMMUNOTHERAPY
NEOVASCULARIZATION inhibitors
GENES
IMMUNE checkpoint inhibitors
CANCER chemotherapy
COMBINED modality therapy
LUNG cancer
GENETIC mutation
Źródło:
Chinese Journal of Lung Cancer; Feb2024, Vol. 27 Issue 2, p81-87, 7p
Terminy geograficzne:
CHINA
Czasopismo naukowe
Szczegóły
Tytuł:
[Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Autorzy:
Zhu XR; Department of Oncology, Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, Shanghai, China.
Zheng LZ; Department of Oncology, Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, Shanghai, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2017 Sep 23; Vol. 39 (9), pp. 646-649.
Typ publikacji:
Journal Article; Review
MeSH Terms:
B7-H1 Antigen/*antagonists & inhibitors
CTLA-4 Antigen/*antagonists & inhibitors
Gastrointestinal Neoplasms/*therapy
Immunotherapy/*methods
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Humans ; Immunotherapy/trends
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Relationship Between Peripheral Blood T Lymphocyte Subsets and Prognosis of Patients with Advanced Non-small Cell Lung Cancer Treated with Camrelizumab
Autorzy:
DONG Changhong
FENG Yan
JIANG Yanting
GAO Jie
JIANG Xiaodong
Pokaż więcej
Temat:
non-small cell lung cancer
cd4+/cd8+ ratio
cd4+t cell
cd8+t cell
anti-pd-1 immunotherapy
camrelizumab
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 3, Pp 185-190 (2024)
Opis pliku:
electronic resource
Relacje:
https://doaj.org/toc/1000-8578
Dostęp URL:
https://doaj.org/article/57b7a06e083a4e909376e7aa5238b349  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
Treatment Strategy and Research Progress of Immune Microenvironment for Liver Metastasis of Non-small Cell Lung Cancer
Autorzy:
SUN Jiaqi
WANG Yudong
Pokaż więcej
Temat:
non-small cell lung cancer
liver metastasis
immunotherapy
immune microenvironment
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 3, Pp 203-209 (2024)
Opis pliku:
electronic resource
Relacje:
https://doaj.org/toc/1000-8578
Dostęp URL:
https://doaj.org/article/705c4e0ff753482b9c0616ea6cfc4c80  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 672

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies